Novel approaches to
cell-based therapies

Angios is an Austrian biotechnology company, specializing in cell-based research.
With our unique approach to target vascular diseases we want to improve patient's lives all over the world.

Background

Blood vessels are the lifelines of our body, delivering required nutrients and removing waste materials. Diseases, impairing their functionality are amongst the biggest threats to global health. Research into vessel biology is currently hampered by the lack of relevant disease models that accurately represent the human environment. Animals, often used in vessel research, deliver only limited insight into vascular disease, require long and expensive observation periods and often do not recapitulate the human phenotype.

Approach

Angios strives to develop new treatments for vascular diseases by pursuing pre-identified targets. We have developed a patented technology that allows for the generation of blood vessels of human origin, utilizing induced pluripotent stem cells (iPSC). This model accurately recapitulates pathologies, found in human patients and provides a unique platform to carry research into vascular diseses.

Gregor Wick

CEO
Vita

Teodor Yordanov

CSO
Vita

Nicole Przysiecki

Scientist
Vita

Florian Regensberger

Project Manager
Vita

David Schorn

Technical Assistant
Vita

Tanila Ben Haddou

Lab manager
Vita

Iris Krainer-Eller

Scientist
Vita

Azarakhsh Oladzad

Senior Scientist
Vita

Jakob Thönig

Intern
Vita

Alexander Hoffmann

Senior Scientist
Vita

Gregor Wick

CEO
Meet Gregor

Josef Penninger, MD

Chairman of the Scientific Advisory Board
Meet Josef

David Hoffmann, PhD

Meet David

Prof. Josef Penninger, MD

Chairman
Vita

Ulrich Granzer, PhD

Granzer Regulatory Consulting & Services
Vita

Carl Hansen, PhD

CEO, abCellera Vancouver
Vita

Prof. Christine Mummery, PhD

Professor of Developmental Biology, Leiden
Vita

Prof. Herbert Tilg, PhD

Professor of internal medicine, Medical University Innsbruck
Vita

Reiner Wimmer, PhD

Scientist, Pharma Reasearch and Early Development, Roche Basel
Vita
Slide 1
Slide 10
Slide 11
Slide 12
Slide 2
Slide 3
Slide 4
Slide 5
Slide 6
Slide 7
Slide 8
Slide 9

The people behind Angios

We are a multi-disciplinary team of scientists that is united by a common goal – to advance our science into therapies. Our team members have different expertise and scientific background, which fosters a highly collaborative work environment. As a new biotech start-up, our company culture is built on teamwork, communication, fun and a passion for science.
Tiroler Krebsforschungsinstitut
Medical University Innsbruck
Tiroler Krebsforschungsinstitut
Medical University Innsbruck
Tiroler Krebsforschungsinstitut
Medical University Innsbruck

We are working together with the following partners.